Angiology. 2012 Feb;63(2):81-3. doi: 10.1177/0003319711421165.
Both oral and intravenous administration of alpha-lipoic acid (ALA) has been investigated as add-on treatment for diabetic peripheral neuropathy. The recent Neurological Assessment of Thioctic Acid in Diabetic Neuropathy (NATHAN) 1 trial has shown that 4-year oral ALA administration is of some value in achieving a clinically meaningful improvement and a slight delay in the progression of neuropathic deficits among patients with mild/moderate diabetic peripheral neuropathy. Despite these promising results, important questions remain to be answered, mainly appropriate patient selection and optimal treatment duration. Moreover, a cost-benefit analysis would be useful.
α-硫辛酸（ALA）的口服和静脉给药已被研究作为糖尿病周围神经病变的附加治疗。最近的糖尿病神经病变硫辛酸神经学评估（NATHAN）1 试验表明，4 年口服 ALA 给药在实现有临床意义的改善和轻度延迟神经病变缺陷进展方面具有一定价值，适用于轻度/中度糖尿病周围神经病变患者。尽管这些结果令人鼓舞，但仍有一些重要的问题有待回答，主要是合适的患者选择和最佳治疗持续时间。此外，成本效益分析将是有用的。
